Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery. / Hankir, Mohammed K.; Kovatcheva-Datchary, Petia; Springer, Rebecca; Hoffmann, Annett; Vogel, Jörg; Seyfried, Florian; Arora, Tulika.

In: Microbiology Spectrum, Vol. 11, No. 3, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hankir, MK, Kovatcheva-Datchary, P, Springer, R, Hoffmann, A, Vogel, J, Seyfried, F & Arora, T 2023, 'Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery', Microbiology Spectrum, vol. 11, no. 3. https://doi.org/10.1128/spectrum.05109-22

APA

Hankir, M. K., Kovatcheva-Datchary, P., Springer, R., Hoffmann, A., Vogel, J., Seyfried, F., & Arora, T. (2023). Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery. Microbiology Spectrum, 11(3). https://doi.org/10.1128/spectrum.05109-22

Vancouver

Hankir MK, Kovatcheva-Datchary P, Springer R, Hoffmann A, Vogel J, Seyfried F et al. Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery. Microbiology Spectrum. 2023;11(3). https://doi.org/10.1128/spectrum.05109-22

Author

Hankir, Mohammed K. ; Kovatcheva-Datchary, Petia ; Springer, Rebecca ; Hoffmann, Annett ; Vogel, Jörg ; Seyfried, Florian ; Arora, Tulika. / Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery. In: Microbiology Spectrum. 2023 ; Vol. 11, No. 3.

Bibtex

@article{c449c304413c49ce9c003a99bbcb1c47,
title = "Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery",
abstract = "Roux-en-Y gastric bypass surgery (RYGB) leads to improved glycemic control in individuals with severe obesity beyond the effects of weight loss alone. Here, We addressed the potential contribution of gut microbiota in mediating this favourable surgical outcome by using an established preclinical model of RYGB. 16S rRNA sequencing revealed that RYGB-treated Zucker fatty rats had altered fecal composition of various bacteria at the phylum and species levels, including lower fecal abundance of an unidentified Erysipelotrichaceae species, compared with both sham-operated (Sham) and body weight-matched to RYGB-treated (BWM) rats. Correlation analysis further revealed that fecal abundance of this unidentified Erysipelotrichaceae species linked with multiple indices of glycemic control uniquely in RYGB-treated rats. Sequence alignment of this Erysipelotrichaceae species identified Longibaculum muris to be the most closely related species, and its fecal abundance positively correlated with oral glucose intolerance in RYGB-treated rats. In fecal microbiota transplant experiments, the improved oral glucose tolerance of RYGB-treated compared with BWM rats could partially be transferred to recipient germfree mice, independently of body weight. Unexpectedly, providing L. muris as a supplement to RYGB recipient mice further improved oral glucose tolerance, while administering L. muris alone to chow-fed or Western style diet-challenged conventionally raised mice had minimal metabolic impact. Taken together, our findings provide evidence that the gut microbiota contributes to weight loss-independent improvements in glycemic control after RYGB and demonstrate how correlation of a specific gut microbiota species with a host metabolic trait does not imply causation. IMPORTANCE Metabolic surgery remains the most effective treatment modality for severe obesity and its comorbidities, including type 2 diabetes. Roux-en-Y gastric bypass (RYGB) is a commonly performed type of metabolic surgery that reconfigures gastrointestinal anatomy and profoundly remodels the gut microbiota. While it is clear that RYGB is superior to dieting when it comes to improving glycemic control, the extent to which the gut microbiota contributes to this effect remains untested. In the present study, we uniquely linked fecal Erysipelotrichaceae species, including Longibaculum muris, with indices of glycemic control after RYGB in genetically obese and glucose-intolerant rats. We further show that the weight loss-independent improvements in glycemic control in RYGB-treated rats can be transmitted via their gut microbiota to germfree mice. Our findings provide rare causal evidence that the gut microbiota contributes to the health benefits of metabolic surgery and have implications for the development of gut microbiota-based treatments for type 2 diabetes.",
keywords = "caloric restriction, germfree mice, glycemic control, gut microbiota, KEYWORDS gastric bypass surgery",
author = "Hankir, {Mohammed K.} and Petia Kovatcheva-Datchary and Rebecca Springer and Annett Hoffmann and J{\"o}rg Vogel and Florian Seyfried and Tulika Arora",
note = "Publisher Copyright: Copyright {\textcopyright} 2023 Hankir et al.",
year = "2023",
doi = "10.1128/spectrum.05109-22",
language = "English",
volume = "11",
journal = "Microbiology spectrum",
issn = "2165-0497",
publisher = "American Society for Microbiology",
number = "3",

}

RIS

TY - JOUR

T1 - Gut Microbiota Contribution to Weight-Independent Glycemic Improvements after Gastric Bypass Surgery

AU - Hankir, Mohammed K.

AU - Kovatcheva-Datchary, Petia

AU - Springer, Rebecca

AU - Hoffmann, Annett

AU - Vogel, Jörg

AU - Seyfried, Florian

AU - Arora, Tulika

N1 - Publisher Copyright: Copyright © 2023 Hankir et al.

PY - 2023

Y1 - 2023

N2 - Roux-en-Y gastric bypass surgery (RYGB) leads to improved glycemic control in individuals with severe obesity beyond the effects of weight loss alone. Here, We addressed the potential contribution of gut microbiota in mediating this favourable surgical outcome by using an established preclinical model of RYGB. 16S rRNA sequencing revealed that RYGB-treated Zucker fatty rats had altered fecal composition of various bacteria at the phylum and species levels, including lower fecal abundance of an unidentified Erysipelotrichaceae species, compared with both sham-operated (Sham) and body weight-matched to RYGB-treated (BWM) rats. Correlation analysis further revealed that fecal abundance of this unidentified Erysipelotrichaceae species linked with multiple indices of glycemic control uniquely in RYGB-treated rats. Sequence alignment of this Erysipelotrichaceae species identified Longibaculum muris to be the most closely related species, and its fecal abundance positively correlated with oral glucose intolerance in RYGB-treated rats. In fecal microbiota transplant experiments, the improved oral glucose tolerance of RYGB-treated compared with BWM rats could partially be transferred to recipient germfree mice, independently of body weight. Unexpectedly, providing L. muris as a supplement to RYGB recipient mice further improved oral glucose tolerance, while administering L. muris alone to chow-fed or Western style diet-challenged conventionally raised mice had minimal metabolic impact. Taken together, our findings provide evidence that the gut microbiota contributes to weight loss-independent improvements in glycemic control after RYGB and demonstrate how correlation of a specific gut microbiota species with a host metabolic trait does not imply causation. IMPORTANCE Metabolic surgery remains the most effective treatment modality for severe obesity and its comorbidities, including type 2 diabetes. Roux-en-Y gastric bypass (RYGB) is a commonly performed type of metabolic surgery that reconfigures gastrointestinal anatomy and profoundly remodels the gut microbiota. While it is clear that RYGB is superior to dieting when it comes to improving glycemic control, the extent to which the gut microbiota contributes to this effect remains untested. In the present study, we uniquely linked fecal Erysipelotrichaceae species, including Longibaculum muris, with indices of glycemic control after RYGB in genetically obese and glucose-intolerant rats. We further show that the weight loss-independent improvements in glycemic control in RYGB-treated rats can be transmitted via their gut microbiota to germfree mice. Our findings provide rare causal evidence that the gut microbiota contributes to the health benefits of metabolic surgery and have implications for the development of gut microbiota-based treatments for type 2 diabetes.

AB - Roux-en-Y gastric bypass surgery (RYGB) leads to improved glycemic control in individuals with severe obesity beyond the effects of weight loss alone. Here, We addressed the potential contribution of gut microbiota in mediating this favourable surgical outcome by using an established preclinical model of RYGB. 16S rRNA sequencing revealed that RYGB-treated Zucker fatty rats had altered fecal composition of various bacteria at the phylum and species levels, including lower fecal abundance of an unidentified Erysipelotrichaceae species, compared with both sham-operated (Sham) and body weight-matched to RYGB-treated (BWM) rats. Correlation analysis further revealed that fecal abundance of this unidentified Erysipelotrichaceae species linked with multiple indices of glycemic control uniquely in RYGB-treated rats. Sequence alignment of this Erysipelotrichaceae species identified Longibaculum muris to be the most closely related species, and its fecal abundance positively correlated with oral glucose intolerance in RYGB-treated rats. In fecal microbiota transplant experiments, the improved oral glucose tolerance of RYGB-treated compared with BWM rats could partially be transferred to recipient germfree mice, independently of body weight. Unexpectedly, providing L. muris as a supplement to RYGB recipient mice further improved oral glucose tolerance, while administering L. muris alone to chow-fed or Western style diet-challenged conventionally raised mice had minimal metabolic impact. Taken together, our findings provide evidence that the gut microbiota contributes to weight loss-independent improvements in glycemic control after RYGB and demonstrate how correlation of a specific gut microbiota species with a host metabolic trait does not imply causation. IMPORTANCE Metabolic surgery remains the most effective treatment modality for severe obesity and its comorbidities, including type 2 diabetes. Roux-en-Y gastric bypass (RYGB) is a commonly performed type of metabolic surgery that reconfigures gastrointestinal anatomy and profoundly remodels the gut microbiota. While it is clear that RYGB is superior to dieting when it comes to improving glycemic control, the extent to which the gut microbiota contributes to this effect remains untested. In the present study, we uniquely linked fecal Erysipelotrichaceae species, including Longibaculum muris, with indices of glycemic control after RYGB in genetically obese and glucose-intolerant rats. We further show that the weight loss-independent improvements in glycemic control in RYGB-treated rats can be transmitted via their gut microbiota to germfree mice. Our findings provide rare causal evidence that the gut microbiota contributes to the health benefits of metabolic surgery and have implications for the development of gut microbiota-based treatments for type 2 diabetes.

KW - caloric restriction

KW - germfree mice

KW - glycemic control

KW - gut microbiota

KW - KEYWORDS gastric bypass surgery

U2 - 10.1128/spectrum.05109-22

DO - 10.1128/spectrum.05109-22

M3 - Journal article

C2 - 37022171

AN - SCOPUS:85163913702

VL - 11

JO - Microbiology spectrum

JF - Microbiology spectrum

SN - 2165-0497

IS - 3

ER -

ID: 360860623